Salmeterol/fluticasone proprionate - Teva Pharmaceutical Industries

Drug Profile

Salmeterol/fluticasone proprionate - Teva Pharmaceutical Industries

Alternative Names: Aerivio Spiromax®; AirDuoTM RespiClick; Fluticasone propionate/salmeterol - Teva; Fluticasone propionate/salmeterol MDI; Fluticasone propionate/salmeterol MDPI; Fluticasone/salmeterol Spiromax® inhalation powder; FS Spiromax; Salmeterol xinafoate/fluticasone propionate - Teva; Salmeterol/fluticasone propionate RespiClick®; Salmeterol/fluticasone propionate Spiromax®

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 30 Jan 2017 Registered for Asthma (In adolescents, In adults) in USA (Inhalation)
  • 01 Dec 2016 Phase-III clinical trials in Asthma (In children) in USA (Inhalation) (NCT02980133)
  • 30 Nov 2016 Teva Branded Pharmaceutical Products, R&D plans a phase III trial for Asthma (In children) in USA (Inhalation) (NCT02980133)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top